pharma · Generalized Myasthenia Gravis · Chronic inflammatory demyelinating polyneuropathy (CIDP)
Argenx
argenx
argenx is a pharma organization headquartered in GENT, BE. Primary therapeutic focus areas include Generalized Myasthenia Gravis, Chronic inflammatory demyelinating polyneuropathy (CIDP), Bullous Pemphigoid, Thyroid Eye
33 Arch Street, Suite 3201, Boston, MA 02110, US HQ
2008 Founded
2,179 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 33 Arch Street, Suite 3201, Boston, MA 02110, US
- Founded
- 2008
- Employees
- 2,179
- Programs
- 32
- Drugs
- 16
- Patents
- 0
ARGX-113-2308
Phase 3 · small molecule · Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
ARGX-113-2308 for Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis is a Phase 3 program (small_molecule) at argenx with 1 ClinicalTrials.gov record(s).
Internal code ARGX-113-2308
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- argenx
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
- Status
- active
- Trials
- 1